Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 Combined With Ningatinib in Advanced Hepatocellular Carcinoma
NCT04601610Phase 2Terminated
- Sponsor
- Alphamab Oncology
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of erfonrilimab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Alphamab Oncology. Primary endpoints: Dose Limiting Toxicity at 1 month and Objective Response Rate at 1 year. Started Jun 2021; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04601610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601610.